MENU
RPRX
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

RPRX stock forecast, quote, news & analysis

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties... Show more

RPRX
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for RPRX with price predictions
Sep 23, 2026

Aroon Indicator for RPRX shows an upward move is likely

RPRX's Aroon Indicator triggered a bullish signal on September 16, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 271 similar instances where the Aroon Indicator showed a similar pattern. In 176 of the 271 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 65%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +0.19% 3-day Advance, the price is estimated to grow further. Considering data from situations where RPRX advanced for three days, in 177 of 311 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.

RPRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The 10-day RSI Indicator for RPRX moved out of overbought territory on September 08, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 14 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 47%.

The Momentum Indicator moved below the 0 level on September 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RPRX as a result. In 40 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 47%.

The Moving Average Convergence Divergence Histogram (MACD) for RPRX turned negative on September 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 22 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 42%.

RPRX moved below its 50-day moving average on September 10, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for RPRX crossed bearishly below the 50-day moving average on September 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RPRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 49%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.757) is normal, around the industry mean (26.046). P/E Ratio (30.995) is within average values for comparable stocks, (40.021). Projected Growth (PEG Ratio) (1.343) is also within normal values, averaging (9.064). RPRX's Dividend Yield (0.016) is considerably higher than the industry average of (0.000). P/S Ratio (12.870) is also within normal values, averaging (436.793).

The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 35 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. RPRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
published Dividends

RPRX paid dividends on September 10, 2026

Royalty Pharma plc RPRX Stock Dividends
А dividend of $0.23 per share was paid with a record date of September 10, 2026, and an ex-dividend date of August 14, 2026. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Nektar Therapeutics (NASDAQ:NKTR), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.25B. The market cap for tickers in the group ranges from 58 to 130.87B. VRTX holds the highest valuation in this group at 130.87B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -2%. For the same Industry, the average monthly price growth was -11%, and the average quarterly price growth was 8%. JAGX experienced the highest price growth at 155%, while LGVN experienced the biggest fall at -61%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 33%. For the same stocks of the Industry, the average monthly volume growth was 104% and the average quarterly volume growth was 25%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 78
Price Growth Rating: 58
SMR Rating: 93
Profit Risk Rating: 92
Seasonality Score: -10 (-100 ... +100)
View a ticker or compare two or three
RPRX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a provider of drug development services

Industry Biotechnology

Industry
Pharmaceuticals Major
Address
110 East 59th Street
Phone
+1 212 883-0200
Employees
100
Web
https://www.royaltypharma.com
Aroon Indicator for RPRX shows an upward move is likely